[THE INVESTOR] As of Oct. 19, Genic (123330) rose 3.68% to 19,700 won (US$17.52). It had declined 6% through the past month. Standard deviation, the risk index for stock price, was 3.1% on the same period of time over one month.

- The Return On Risk, -1.9, is in the lower class, it is lower than the industrial index - All related stocks also increase. Chemicals industry +0.34% - Target price KRW 30,000, has 53% disparate to increase compared with stock price. - Institutions and Foreigners sell, Individuals buy - Turnover Rate and Price Range both proper - The main shareholding group is Individuals

Compared with its close competitors within the same industry, KOSDAQ, the monthly volatility of Genic was around the average of that of its peer group, but the investment return for 1 month was at an absolutely low level. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -1.9%. As bearish stock price trend, the return-on-risk was poor, compared with its peer group. Moreover, compared with the KOSDAQ industry, the return-on-risk is below the industrial mean, -0.7, and thus it is hard to say that the industrial comparison performance was positive. 

While institutions have been selling Genic during the past 7 trading days, foreigners have been buying during the past 3 trading days. As a shareholding sum by investor group for the past 4 weeks, foreigners have sold 28,905 shares with maintenance of a selling position and institutions have sold 29,987 shares with a selling trend. However, during the same period, individuals have bought 58,892 shares with an increasing position. 

Cumulated shareholdings per investor group (1Mo)		Total shareholdings per investor group

By HeRo (hero@heraldcorp.com) 

This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.